NBIX
Neurocrine Biosciences
Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: NBIX
- Earnings
EPS in 2026 (TTM): $7.05
Last Report Period Date: Jun 30, 2026
As of August 2026, NBIX's current EPS stands at $7.05, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $4.81, which marks an increase compared to its EPS of $3.4 in 2024. NBIX reported an EPS of $1.43 for the quarterly report ending on Jun 30, 2026.
NBIX earnings history
For 2025, Neurocrine Biosciences's EPS was $4.81, an increase of 41.5% from $3.4 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $1.43, showing a 31.2% increase from the same quarter last year. For the twelve months ending June 2026, the EPS is $7.05. For the year 2024, the yearly earnings per share was $3.4, marking an increase of 32.8% from 2023.
NBIX earnings chart
NBIX EPS growth history
During the last 12 months, Neurocrine Biosciences has seen an EPS growth of 31.2% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 44% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 1.9%.
NBIX Earnings Waterfall
NBIX Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| PFE Pfizer Inc | 19.07 | -3.5% | -37.4% | -3.7% |
| ANIP Ani Pharmaceuticals Inc | 19.22 | 436.5% | N/A | N/A |
| NBIX Neurocrine Biosciences Inc | 24.05 | 41.5% | 44% | 1.9% |
| RPRX Royalty Pharma plc - Class A | 30.03 | -6.8% | 161.6% | 6.3% |
| LLY Lilly(Eli) & Company | 39.92 | 95.6% | 49.2% | 27.5% |
| ABBV Abbvie Inc | 121.21 | -1.3% | -29.1% | -2.8% |
| RGEN Repligen Corp | 193.28 | 289.1% | -36.2% | -5.3% |
All data is based on quarterly TTM periods, unless otherwise specified.